

Butterfly Medical Ltd.

- **Investment Rational**

Minimally-invasive treatment for enlarged prostate (BPH), the most prevalent disease in aging men.

- Less invasive procedure compared to other treatments
- No capital equipment and minimal training
- Permanent implant, yet fully reversible
- 70+ patients enrolled so far in a multi-center trial, showing good safety and efficacy outcomes

4 M&A deals and 1 IPO in the last 5 years of companies developing solutions for BPH
Board includes Dr. Shimon Eckhouse and Steffen Hovard (ex-president US-Surgical, Coloplast)

- **Business Strategy**

- Ideal for office/ outpatient use in the US due to high reimbursement
- US launch is planned for late 2024, once we complete the US Pivotal trial
- Employing a full-time Chief Commercial Officer in the US that is already engaging urologists
- Clear path to US commercialization with the building of the commercial team, experienced physicians from the Pivotal trial and a reimbursement code identified

- **Core Technology**

The Butterfly implant is designed to fit the unique anatomy of the prostate and dilate the obstructed area to restore urine flow in men suffering from BPH symptoms. Unlike existing BPH treatments, the Butterfly procedure does not require removing or burning tissue or puncturing of the prostate capsule, making it simple, faster and safer. The procedure relies on the urologists own equipment, making it intuitive, with minimal training requirement.

- **Product Profile/Pipeline**

Product in design-freeze, approved for use by FDA in IDE trial and CE Marked.
3 patents, 2 already granted in the US and in other countries
New delivery system under development, that will reduce procedure time even further

- **What's Next?**

US Pivotal trial launching in the coming weeks (first patients in April 22).
Additional trials in Israel and in Europe launching this year.
Raised about \$12M in seed (incubator) and A,B rounds.
Launching Round C to finance US trial and launch. Part of the round already committed.